evans blue has been researched along with sulindac in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cottin, T; Giannis, A; Kalomenidis, I; Kollintza, A; Moschos, C; Papiris, S; Psallidas, I; Roussos, C; Stathopoulos, GT | 1 |
2 other study(ies) available for evans blue and sulindac
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A sulindac analogue is effective against malignant pleural effusion in mice.
Topics: Animals; Capillary Permeability; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Evans Blue; Inflammation Mediators; Mice; Mice, Inbred C57BL; Pleural Effusion, Malignant; Pleural Neoplasms; Sulindac; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |